Lineage Cell Therapeutics, Inc.
Business
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell replacement therapies for serious medical conditions including dry age-related macular degeneration, spinal cord injury, hearing loss, and type 1 diabetes. The company manufactures mature, differentiated cells derived from pluripotent stem cells using its proprietary AlloSCOPE platform, which enables scalable, cost-effective production of off-the-shelf cell products. Its lead program OpRegen for geographic atrophy is in Phase 2a development under a collaboration with Roche, while OPC1 for spinal cord injury is in Phase 1 development, and additional programs in preclinical or research stages target hearing loss, vision loss, and diabetes.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 15 | 9 | 9 | 15 | — | |
| Cost of royalties | 146,000 | 334,000 | — | — | — | |
| Research and development | 18 | 12 | 16 | 14 | 34 | |
| General and administrative | 18 | 18 | 17 | 23 | 18 | |
| Loss on impairment of intangible asset (Note 6 and Note 13) | 15 | 0 | — | — | — | |
| Total operating expenses | 51 | 31 | 34 | — | — | |
| Loss from operations | −37 | −21 | −25 | −23 | −49 | |
| Interest income, net | 2 | 2 | 2 | 829,000 | — | |
| Loss on marketable equity securities, net | −8,000 | −8,000 | −176,000 | −2 | — | |
| Change in fair value of warrant liability | −36 | 2 | 0 | 225,000 | — | |
| Foreign currency transaction gain (loss), net | 2 | −269,000 | −544,000 | — | — | |
| Other income (expense), net | −132,000 | −670,000 | 542,000 | −2 | 1 | |
| Total other income (expenses) | −32 | 3 | 1 | −3 | 6 | |
| LOSS BEFORE INCOME TAXES | −69 | −19 | −23 | −26 | −43 | |
| Income tax benefit | 5 | 0 | 2 | −500,000 | — | |
| NET LOSS | −63 | −19 | −21 | −26 | −43 | |
| Net (income) loss attributable to noncontrolling interest | −166,000 | −27,000 | −7,000 | 80,000 | 251,000 | |
| NET LOSS ATTRIBUTABLE TO LINEAGE | −64 | −19 | −21 | −26 | −43 | |
| Net loss per common share attributable to Lineage basic | −0.28 | −0.09 | −0.12 | −0.15 | −0.26 | |
| Net loss per common share attributable to Lineage diluted | −0.28 | −0.09 | −0.12 | −0.15 | — | |
| Weighted-average common shares used to compute net loss per common share, basic | 230 | 200 | 173 | 170 | 165 | |
| Weighted-average common shares used to compute net loss per common share, diluted | 230 | 200 | 173 | 170 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 41 | 46 | 35 | 11 | 56 | |
| Marketable securities | 15 | 2 | 50,000 | 47 | 3 | |
| Accounts receivable | 891,000 | 638,000 | 700,000 | 300,000 | — | |
| Prepaid expenses and other current assets | 2 | 3 | 2 | 2 | 2 | |
| Total current assets | 59 | 51 | 38 | 60 | 112 | |
| Property and equipment, net | 3 | 2 | 2 | 6 | 5 | |
| Operating lease right-of-use assets | 2 | 2 | 3 | — | — | |
| Deposits and other long-term assets | 558,000 | 614,000 | 577,000 | 627,000 | — | |
| Goodwill | 11 | 11 | 11 | 11 | 11 | |
| Intangible assets, net | 32 | 47 | 47 | 47 | 47 | |
| Deferred tax asset, net | 6 | 0 | — | — | — | |
| TOTAL ASSETS | 113 | 113 | 101 | 124 | 175 | |
| Accounts payable and accrued liabilities | 7 | 5 | 6 | 9 | 28 | |
| Operating lease liabilities, current portion | 816,000 | 1 | 830,000 | 916,000 | 801,000 | |
| Finance lease liabilities, current portion | 37,000 | 55,000 | 52,000 | 36,000 | 30,000 | |
| Deferred revenues, current portion | 3 | 7 | 11 | 9 | 18 | |
| Total current liabilities | 11 | 14 | 18 | 19 | 47 | |
| Deferred tax liability, net | 22,000 | 273,000 | 273,000 | 2 | 2 | |
| Deferred revenues, net of current portion | 12 | 14 | 19 | 28 | 32 | |
| Operating lease liabilities, net of current portion | 2 | 1 | 2 | 3 | 2 | |
| Finance lease liabilities, net of current portion | 32,000 | 67,000 | 91,000 | 84,000 | 30,000 | |
| Warrant liabilities | 44 | 6 | 0 | — | — | |
| TOTAL LIABILITIES | 69 | 36 | 39 | 52 | 84 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common shares, no par value, 450,000 shares authorized as of December 31, 2025 and 2024; 243,122 and 220,416 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 515 | 485 | 451 | 440 | 435 | |
| Accumulated other comprehensive loss | −4 | −3 | −3 | −4 | −5 | |
| Accumulated deficit | −467 | −403 | −385 | −363 | −337 | |
| Lineage's shareholders' equity | 45 | 78 | 63 | 73 | 92 | |
| Noncontrolling deficit | −1 | −1 | −1 | −1 | −1 | |
| Total shareholders equity | 43 | 77 | 62 | 72 | 91 | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 113 | 113 | 101 | 124 | 175 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Issuance costs for common stock warrant liabilities | 183,000 | 688,000 | 0 | — | — | |
| Accretion of income on marketable debt securities | −44,000 | −229,000 | −679,000 | −501,000 | — | |
| Depreciation and amortization expense | 699,000 | 587,000 | 562,000 | 582,000 | — | |
| Change in right-of-use assets and liabilities | −58,000 | −42,000 | 91,000 | −35,000 | 14,000 | |
| Amortization of intangible assets | 0 | 22,000 | 130,000 | 100,000 | 210,000 | |
| Stock-based compensation | 5 | 5 | 5 | 4 | 4 | |
| Deferred income tax benefit | −5 | 0 | −2 | 0 | — | |
| Foreign currency remeasurement | −2 | 273,000 | — | — | — | |
| Accounts receivable | −316,000 | 106,000 | −446,000 | 50 | −857,000 | |
| Prepaid expenses and other current assets | 46,000 | 489,000 | −418,000 | 446,000 | −72,000 | |
| Accounts payable and accrued liabilities | 2 | −2 | −2 | −19 | 22 | |
| Deferred revenue | −6 | −8 | −8 | −13 | — | |
| Net cash used in operating activities | −19 | −23 | −29 | 1 | −24 | |
| Proceeds from the sale of marketable equity securities | 0 | 18,000 | 196,000 | 0 | — | |
| Purchases of marketable debt securities | −15 | −9 | −16 | −53 | — | |
| Maturities of marketable debt securities | 2 | 7 | 63 | 8 | — | |
| Purchase of equipment | −522,000 | −565,000 | −674,000 | −413,000 | −340,000 | |
| Net cash used in investing activities | −13 | −2 | 46 | −46 | 10 | |
| Proceeds from employee options exercised | 1 | 229,000 | 88,000 | 648,000 | 7 | |
| Proceeds from exercise of warrants | 319,000 | 0 | 0 | 991,000 | — | |
| Common shares received and retired for employee taxes paid | −16,000 | −23,000 | −37,000 | −17,000 | — | |
| Payment of financed insurance premium | −684,000 | −171,000 | 0 | — | — | |
| Payment of finance lease liabilities | −59,000 | −54,000 | −54,000 | −32,000 | — | |
| Net cash provided by financing activities | 27 | 36 | 6 | 2 | 37 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 396,000 | −95,000 | −250,000 | −873,000 | — | |
| NET DECREASE (INCREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | −5 | 10 | 24 | −44 | 23 | |
| Cash paid for interest | 29,000 | 9,000 | 10,000 | 13,000 | 13,000 | |
| Financing costs in accounts payable and accrued liabilities | 3,000 | 179,000 | 0 | — | — | |
| Fair value of warrant liability recognized upon issuance in registered direct financing | 2 | 8 | 0 | — | — | |
| Financed insurance premium | 0 | 855,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lineage Cell Therapeutics, Inc.'s CIK number?
Lineage Cell Therapeutics, Inc.'s SEC CIK number is 0000876343 (876343). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lineage Cell Therapeutics, Inc.'s SEC filings?
All of Lineage Cell Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Lineage Cell Therapeutics, Inc. last report earnings?
Lineage Cell Therapeutics, Inc. (LCTX) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219421). This is Lineage Cell Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Lineage Cell Therapeutics, Inc.'s most recent earnings 8-K?
Lineage Cell Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219421. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Lineage Cell Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →